New biotech incubator opens at Berkeley; Adeona inks $17.5M development pact;

 @FierceBiotech: Burrill: Focus on patients, not molecules. Report | Follow @FierceBiotech 

 @JohnCFierce: Whatever else you might say about Cytori, it won't make any believers at the FDA with a small stem cell trial like this. Report | Follow @JohnCFierce

> UC Berkeley is getting into the biotech incubator game. Hoping to achieve some of the success of UC San Francisco's incubator, which has helped spawn 28 companies, the university is cutting the ribbon on its QB3 [email protected] The first tenant: Apersys, which has taken 100 square feet of space to start pursuing its dream of developing a new way to "grow nerve cells used in biology experiments," according to the San Francisco Business Times. Story

> Ann Arbor, MI-based Adeona Pharmaceuticals is collecting a $2.5 million upfront from its new development pact with Sweden's Meda AB. Adeona will get up to $15 million in milestones from the deal, which gives Meda an exclusive sublicense to all of Adeona's patents covering the use of flupirtine for fibromyalgia. Release

> Bayer has won FDA approval of Natazia, a new birth control pill that can deliver varying doses of a hormone over a 28-day cycle. Report

> Amsterdam-based Fornix Biosciences is urging investors to back the sale of its allergy unit. Story

> Acceleron Pharma launched a Phase II clinical trial with ACE-031 in patients with Duchenne Muscular Dystrophy. Release

And Finally... A team of scientists has concluded that there's genetic evidence to suggest that modern humans and Neanderthals not only lived together but also engaged in interspecies mating. Report

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.